GH Research PLC (NASDAQ:GHRS) Receives $30.86 Consensus Price Target from Analysts

Shares of GH Research PLC (NASDAQ:GHRS - Get Free Report) have earned an average rating of "Buy" from the seven analysts that are covering the stock, MarketBeat reports. Seven investment analysts have rated the stock with a buy recommendation. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $30.86.

GHRS has been the subject of several analyst reports. Guggenheim started coverage on shares of GH Research in a research note on Thursday, March 13th. They issued a "buy" rating and a $32.00 price objective for the company. Royal Bank of Canada began coverage on GH Research in a research note on Friday, March 7th. They set an "outperform" rating and a $31.00 price target for the company. HC Wainwright reaffirmed a "buy" rating and issued a $40.00 price objective on shares of GH Research in a research report on Monday, January 27th. Cantor Fitzgerald assumed coverage on GH Research in a research note on Thursday, February 13th. They issued an "overweight" rating and a $14.00 target price on the stock. Finally, Stifel Nicolaus boosted their target price on shares of GH Research from $18.00 to $32.00 and gave the company a "buy" rating in a research note on Thursday, February 27th.

Institutional Investors Weigh In On GH Research

Hedge funds have recently made changes to their positions in the company. Woodline Partners LP raised its holdings in shares of GH Research by 112.0% in the fourth quarter. Woodline Partners LP now owns 78,949 shares of the company's stock valued at $553,000 after acquiring an additional 41,711 shares in the last quarter. Two Sigma Investments LP purchased a new position in GH Research during the 4th quarter valued at about $117,000. Millennium Management LLC bought a new stake in shares of GH Research in the 4th quarter valued at about $145,000. BNP Paribas Financial Markets purchased a new stake in shares of GH Research in the 4th quarter worth approximately $44,000. Finally, AdvisorShares Investments LLC boosted its stake in shares of GH Research by 15.4% during the fourth quarter. AdvisorShares Investments LLC now owns 36,011 shares of the company's stock valued at $252,000 after purchasing an additional 4,806 shares in the last quarter. 56.90% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

GH Research Stock Up 2.3 %

GHRS traded up $0.23 during trading on Tuesday, reaching $10.09. The company had a trading volume of 261,769 shares, compared to its average volume of 166,562. The business has a 50 day simple moving average of $11.92 and a 200-day simple moving average of $9.42. The stock has a market cap of $524.96 million, a P/E ratio of -12.77 and a beta of 0.84. GH Research has a 52 week low of $6.00 and a 52 week high of $20.50.

GH Research (NASDAQ:GHRS - Get Free Report) last released its earnings results on Thursday, February 27th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.06. As a group, equities research analysts expect that GH Research will post -0.8 EPS for the current fiscal year.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).